Price History
Investment Checklist
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Trend
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Price Action
Support & Resistance Levels
Volume Analysis
Recent MA Crossovers
Stop Loss Levels
Fixed Risk
Technical Levels
Moving Averages
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹2,319 Cr | ₹2,550 Cr | ₹2,410 Cr | ₹2,604 Cr |
| Net Profit | ₹589 Cr | ₹662 Cr | ₹545 Cr | ₹583 Cr |
| EPS | ₹22.20 | — | ₹20.49 | ₹21.98 |
| Operating Profit | ₹825 Cr | ₹972 Cr | ₹848 Cr | ₹904 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Biocon Limited | ₹418.50 | +3.70% | 177.4 | ₹67.83K Cr mid Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 25 Jul 2025 | Dividend - Rs 30 Per Share | DIVIDEND |
| 02 Aug 2024 | Dividend - Rs 30 Per Share | DIVIDEND |
| 11 Aug 2023 | Dividend - Rs 30 Per Share | DIVIDEND |
| 11 Aug 2022 | Dividend - Rs 30 Per Share | DIVIDEND |
| 17 Aug 2021 | Dividend - Rs 20 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for DIVISLAB
View All
Divi's Labs slips 3% on margin worries; analysts positive on growth outlook
In the March quarter, Divi's Laboratories reported net profit at ₹751 crore, as compared to ₹662 crore a year ago, up 13.4 per cent year-on-year (Y-o-Y)
Divi's Laboratories analysts remain divided on prospects after Q4 results; Check key triggers & risks
Kotak Institutional Equities, who is bearish on Divi's Laboratories, said that the stock's current valuations of 49 times its estimated price-to-earnings ratio for FY28, is already pricing in growth potential.
Six pharma stocks that should be on your radar today over various news triggers
It was a busy weekend for pharma stocks as four of them — Divi's Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results. Meanwhile, Lupin marked its entry into the Chinese market, while Glenmark Pharma's US arm settled an anti-trust litigation. Here's a look at these names in detail: